Autolus: FDA approves new CAR-T competitor to Gilead's Tecartus
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the brand name Aucatzyl.
Read full article »
Autolus is a biopharmaceutical company that develops and commercializes T-cell immunotherapies for the treatment of cancer.
Read more